Heart Repair Venture Undeterred By Risk; Is “Biopacing” Next For Medtronic?

MG Biotherapeutics' initial focus on autologous cell repair of the heart, if successful, will give the joint venture a "commercial bridge" to further combination product development, Genzyme Exec VP Earl Collier said at Medtronic's annual investor conference Oct. 5